{
    "nct_id": "NCT05293496",
    "official_title": "A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* 1. Ability to provide and document informed consent and willing and able to comply with all study procedures.\n* Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma.\n* Participants have received approved therapies according to their diagnosis.\n* Participants must have an available tumor tissue sample. A fresh tumor biopsy may be performed if no archival sample is available.\n* Eastern Cooperative Oncology Group performance status of less than or equal to 2.\n* Life expectancy of at least 12 weeks.\n* Evidence of measurable tumor for evaluation\n* Acceptable end organ function according to laboratory results.\n* Patients must agree to use highly-effective contraception during the study, and not donate sperm or ova.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another malignancy that required treatment within the past 2 years. Participants who have had curative therapy for non-melanomatous skin cancer, localized prostate cancer (Gleason score < 6), or carcinoma in situ are eligible for the study.\n* Active viral, bacterial, or fungal infection requiring systemic treatment within 1 week of initiation of study drug. Participants are eligible after SARS CoV 2-related symptoms have fully recovered for ≥ 72 hours.\n* History of immunodeficiency. Participants with HIV are eligible if they have a CD4+ count ≥ 300/µL, undetectable viral load, and maintained on antiretroviral therapy for a minimum of 4 weeks.\n* Prior autologous/allogeneic stem cell or tissue/solid organ transplant\n* Prior treatment with MGD009, enoblituzumab, or other B7-H3 targeted agents for cancer.\n* Clinically significant cardiovascular disease, lung compromise, venous insufficiency, or gastrointestinal disorders.\n* Participants with greater than Grade 1 peripheral neuropathy.\n* Participants who have a history of severe adverse events (AEs) from immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or CTLA-4 inhibitors). All other AEs from prior immune checkpoint inhibitors must be resolved to Grade 1 or less. Participants with any grade neurologic toxicity from prior immune checkpoint inhibitors are excluded.\n* Pleural effusion or ascites. Trace pleural or peritoneal fluid is not exclusionary.\n* History of Guillain-Barre syndrome, myasthenia gravis, or other autoimmune sensory or motor neuropathies.",
    "miscellaneous_criteria": ""
}